A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
Children and young adults with gastrointestinal stromal tumors (GIST) will be treated with
sunitinib. The safety (including pharmacokinetics) and tolerability of sunitinib will be
studied in these patients. In addition, tumor responses and overall survival will be
assessed.